A Single Center, Prospective Study of Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 60
Healthy Volunteers: f
View:
• Aged between 20 and 60 (male or female)
• Diagnosed chronic decompensated hepatitis B cirrhosis with a course of more than 5 years
• Not suitable for liver transplantation or there is no donor liver source
• No serious bleeding tendency or active bleeding
• No hepatic encephalopathy
• After strict medical conservative treatment for more than 6 months, there was no relief of symptoms or significant improvement of quality of life score
• Subjects voluntarily participate in this study and sign informed consent
Locations
Other Locations
China
Haikou People's Hospital
RECRUITING
Haikou
Contact Information
Primary
Xiaoxi Huang, PHD
huangxiaoxi@xibaozhiliao.cn
86-0898-66151200
Time Frame
Start Date: 2021-12-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 30
Treatments
Experimental: UC-MSC infusion
UC-MSC infusion by intravenus, 1\*10\^8 cells/dose, 2 doses (apart from 24weeks)
Related Therapeutic Areas
Sponsors
Leads: Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.